ArticleFrontiers in immunology2026
Real-world experience with first-line pembrolizumab plus chemotherapy in Vietnamese patients with stage IV esophageal squamous cell carcinoma.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Esophageal squamous cell carcinoma (ESCC) remains a major cause of cancer-related mortality in Asia. Pembrolizumab in combination with chemotherapy has become a standard first-line option based on phase III trial data, but real-world evidence from Vietnam is lacking. This study examined the clinical characteristics, disease course, and treatment-related toxicities of Vietnamese patients with stage IV ESCC receiving this regimen. Methods: We conducted a single-center, single-arm, retrospective analysis of 53 patients with stage IV ESCC treated with pembrolizumab plus platinum- and fluoropyrimidine-based chemotherapy. Information on demographics, clinical presentation, pathology, biomarker status, treatment regimens, patterns of progression or recurrence, and adverse events (AEs) was collected from electronic health records. Results: The mean age was 59 years, with nearly all patients being male. Most presented with advanced T3/N2 disease and dysphagia at diagnosis. PD-L1 status was unavailable in about one-third of cases. Common chemotherapy backbones were CF (50.9%) and XELOX/SOX (24.5%). Progression or recurrence was documented in 24.5% of patients, and 20.8% occurred within six months. Lymph nodes were the most frequent site of progression, followed by local and distant recurrence. Hematologic toxicities were common, including neutropenia (43.4% all grades, 13.2% grade ≥3) and anemia (50.9% all grades). Nausea (20.8%) and diarrhea (5.7%) were the main gastrointestinal toxicities. Immune-related events included hypothyroidism (3.8%) and pneumonitis (3.8%). Conclusions: In this Vietnamese cohort, pembrolizumab plus chemotherapy showed a manageable safety profile and recurrence patterns consistent with those reported internationally. These findings add region-specific real-world evidence and underline the importance of broader multi-center studies with longer follow-up to inform practice in advanced ESCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.